NCT04370704

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.

Conditions

• Melanoma

Interventions

Type	Name	Description
DRUG	INCAGN02385	INCAGN02385 administered intravenously
DRUG	INCAGN02390	INCAGN02390 administered intravenously
DRUG	INCMGA00012.	INCMGA00012 administered intravenously

Timeline

• Start date: 2020-07-27
• Primary completion: 2025-08-25
• Completion: 2025-08-25
• First posted: 2020-05-01
• Last updated: 2025-10-03

Locations

17 sites across 2 countries: United States, Australia

Regulatory

• FDA-regulated drug study